Posted by Michael Wonder on 01 Jun 2026
Samsung Bioepis launches Opuviz (aflibercept) 40 mg/mL vial across Europe, to treat ophthalmic conditions
29 May 2026 - Samsung Bioepis today announced the launch of Opuviz 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea (aflibercept), across Europe, starting today.
Opuviz marks the fifth biosimilar product to be directly commercialised by Samsung Bioepis.
